PMID- 32733803
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240329
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - Angustoline Inhibited Esophageal Tumors Through Regulating 
      LKB1/AMPK/ELAVL1/LPACT2 Pathway and Phospholipid Remodeling.
PG  - 1094
LID - 10.3389/fonc.2020.01094 [doi]
LID - 1094
AB  - Esophageal cancer is a type of gastrointestinal carcinoma and is among the 10 
      most common causes of cancer death worldwide. However, the specific mechanism and 
      the biomarkers in the proliferation and metastasis of esophageal tumors are still 
      unclear. Therefore, the development of several natural products which could 
      inhibit esophageal tumors deserve attention. In the present study, different 
      sources of cancer cells were used to select the sensitive cell line (esophageal 
      cancer cell KYSE450) and the proper dose of angustoline, which were utilized in 
      the following cell viability, migration and invasion assays. Then the lipidomic 
      detection of clinical samples (tissue and blood plasma) from esophageal cancer 
      patients was performed, to screen out the specific phospholipid metabolites [PC 
      (16:0/18:1) and LPC (16:0)]. Considering lysophosphatidylcholine acyltransferase 
      2 (LPCAT2) was tightly relative with phospholipids conversion, 
      serine/threonine-protein kinase 11 (LKB1), 5'-monophosphate (AMP)-activated 
      protein kinase (AMPK) and embryonic lethal, and abnormal vision, drosophila-like 
      1 (ELAVL1) were investigated, to evaluate their expression levels in esophageal 
      tumor tissue and KYSE450 cells. Additionally, KYSE450 tumor bearing mouse model 
      was constructed, the role of angustoline in inhibiting esophageal tumors through 
      regulating LKB1/AMPK/ELAVL1/LPCAT2 pathway was validated, and found that the 
      conversion from LPC (16:0) to PC (16:0/18:1) was blocked by angustoline in some 
      degree. The above results for the first time proved that angustoline suppressed 
      esophageal tumors through activating LKB1/AMPK and inhibiting ELAVL1/LPCAT2, 
      which consequently blocked phospholipid remodeling from LPC (16:0) to PC 
      (16:0/18:1).
CI  - Copyright (c) 2020 Li, Zhang, Zhang, Yao, Yang, Fan and Zheng.
FAU - Li, Huiying
AU  - Li H
AD  - Key Laboratory of Quality and Safety Control for Milk and Dairy Products of 
      Ministry of Agriculture and Rural Affairs, Institute of Animal Science, Chinese 
      Academy of Agricultural Sciences, Beijing, China.
FAU - Zhang, Cheng
AU  - Zhang C
AD  - Department of Cardiothoracic Surgery, First Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Zhang, Min
AU  - Zhang M
AD  - Department of Cardiothoracic Surgery, First Affiliated Hospital of Chongqing 
      Medical University, Chongqing, China.
FAU - Yao, Qianqian
AU  - Yao Q
AD  - Key Laboratory of Quality and Safety Control for Milk and Dairy Products of 
      Ministry of Agriculture and Rural Affairs, Institute of Animal Science, Chinese 
      Academy of Agricultural Sciences, Beijing, China.
FAU - Yang, Huaigu
AU  - Yang H
AD  - Key Laboratory of Quality and Safety Control for Milk and Dairy Products of 
      Ministry of Agriculture and Rural Affairs, Institute of Animal Science, Chinese 
      Academy of Agricultural Sciences, Beijing, China.
FAU - Fan, Linlin
AU  - Fan L
AD  - Key Laboratory of Quality and Safety Control for Milk and Dairy Products of 
      Ministry of Agriculture and Rural Affairs, Institute of Animal Science, Chinese 
      Academy of Agricultural Sciences, Beijing, China.
FAU - Zheng, Nan
AU  - Zheng N
AD  - Key Laboratory of Quality and Safety Control for Milk and Dairy Products of 
      Ministry of Agriculture and Rural Affairs, Institute of Animal Science, Chinese 
      Academy of Agricultural Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7358378
OTO - NOTNLM
OT  - AMPK
OT  - ELAVL1
OT  - LKB1
OT  - LPCAT2
OT  - esophageal cancer
OT  - lipidomics
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
PMCR- 2020/01/01
CRDT- 2020/08/01 06:00
PHST- 2020/01/06 00:00 [received]
PHST- 2020/06/01 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.01094 [doi]
PST - epublish
SO  - Front Oncol. 2020 Jul 7;10:1094. doi: 10.3389/fonc.2020.01094. eCollection 2020.